Literature DB >> 23670727

Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling?

Dan G Duda, Lance L Munn, Rakesh K Jain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23670727      PMCID： PMC3672078          DOI： 10.1093/jnci/djt114

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  21 in total

1.  Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

Authors:  Adrian M Jubb; Herbert I Hurwitz; Wei Bai; Eric B Holmgren; Patti Tobin; A Steven Guerrero; Fairooz Kabbinavar; Scott N Holden; William F Novotny; Gretchen D Frantz; Kenneth J Hillan; Hartmut Koeppen
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

Review 2.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Authors:  Harold F Dvorak
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

Review 3.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

4.  Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

Authors:  Lei Xu; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Daniel C Chung; Gregory Y Lauwers; Rekha Samuel; Paul Shellito; Brian G Czito; Pei-Chun Lin; Martin Poleski; Rex Bentley; Jeffrey W Clark; Christopher G Willett; Rakesh K Jain
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

Review 5.  Biomarkers of response and resistance to antiangiogenic therapy.

Authors:  Rakesh K Jain; Dan G Duda; Christopher G Willett; Dushyant V Sahani; Andrew X Zhu; Jay S Loeffler; Tracy T Batchelor; A Gregory Sorensen
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

6.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.

Authors:  Christopher G Willett; Dan G Duda; Emmanuelle di Tomaso; Yves Boucher; Marek Ancukiewicz; Dushyant V Sahani; Johanna Lahdenranta; Daniel C Chung; Alan J Fischman; Gregory Y Lauwers; Paul Shellito; Brian G Czito; Terence Z Wong; Erik Paulson; Martin Poleski; Zeljko Vujaskovic; Rex Bentley; Helen X Chen; Jeffrey W Clark; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

7.  Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Authors:  Andrew X Zhu; Dushyant V Sahani; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A Catalano; Vivek Sindhwani; Lawrence S Blaszkowsky; Sam S Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey Meyerhardt; Jeffrey W Clark; Eunice L Kwak; Aram F Hezel; Rebecca Miksad; Thomas A Abrams; Peter C Enzinger; Charles S Fuchs; David P Ryan; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

Review 8.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Authors:  Rakesh K Jain
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

9.  Tumor induction of VEGF promoter activity in stromal cells.

Authors:  D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

10.  Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.

Authors:  Christian Stockmann; Andrew Doedens; Alexander Weidemann; Na Zhang; Norihiko Takeda; Joshua I Greenberg; David A Cheresh; Randall S Johnson
Journal:  Nature       Date:  2008-11-09       Impact factor: 49.962
View more
  11 in total

1.  Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Authors:  Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2018-03-14       Impact factor: 17.956

Review 2.  Obesity and Cancer: An Angiogenic and Inflammatory Link.

Authors:  Dai Fukumura; Joao Incio; Ram C Shankaraiah; Rakesh K Jain
Journal:  Microcirculation       Date:  2016-04       Impact factor: 2.628

3.  A conceptual review on systems biology in health and diseases: from biological networks to modern therapeutics.

Authors:  Pramod Rajaram Somvanshi; K V Venkatesh
Journal:  Syst Synth Biol       Date:  2013-09-18

Review 4.  Computational systems biology approaches to anti-angiogenic cancer therapeutics.

Authors:  Stacey D Finley; Liang-Hui Chu; Aleksander S Popel
Journal:  Drug Discov Today       Date:  2014-10-05       Impact factor: 7.851

Review 5.  Systems biology of angiogenesis signaling: Computational models and omics.

Authors:  Yu Zhang; Hanwen Wang; Rebeca Hannah M Oliveira; Chen Zhao; Aleksander S Popel
Journal:  WIREs Mech Dis       Date:  2021-12-30

6.  Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach.

Authors:  S Sharan; S Woo
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-08

7.  Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.

Authors:  Stacey D Finley; Manjima Dhar; Aleksander S Popel
Journal:  Front Oncol       Date:  2013-07-30       Impact factor: 6.244

8.  Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts.

Authors:  Princess I Imoukhuede; Aleksander S Popel
Journal:  Cancer Med       Date:  2014-01-22       Impact factor: 4.452

9.  Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.

Authors:  Satish Sharan; Sukyung Woo
Journal:  Front Pharmacol       Date:  2015-02-20       Impact factor: 5.810

10.  Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells.

Authors:  Kerri-Ann Norton; Zheyi Han; Aleksander S Popel; Niranjan B Pandey
Journal:  Onco Targets Ther       Date:  2014-09-09       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.